Summit Therapeutics (SMMT) Competitors $21.20 -0.08 (-0.38%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$21.36 +0.16 (+0.78%) As of 08:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SMMT vs. TAK, ARGX, ONC, BNTX, TEVA, ITCI, GMAB, RDY, ASND, and VTRSShould you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. Summit Therapeutics vs. Its Competitors Takeda Pharmaceutical argenex BeOne Medicines BioNTech Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Takeda Pharmaceutical (NYSE:TAK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability. Do analysts recommend TAK or SMMT? Summit Therapeutics has a consensus target price of $34.67, suggesting a potential upside of 63.52%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Summit Therapeutics 2 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.79 Do insiders and institutionals hold more shares of TAK or SMMT? 9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is TAK or SMMT more profitable? Takeda Pharmaceutical has a net margin of 2.36% compared to Summit Therapeutics' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 10.64% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical2.36% 10.64% 5.14% Summit Therapeutics N/A -62.87%-51.61% Does the media refer more to TAK or SMMT? In the previous week, Summit Therapeutics had 11 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for Summit Therapeutics and 3 mentions for Takeda Pharmaceutical. Summit Therapeutics' average media sentiment score of 0.75 beat Takeda Pharmaceutical's score of 0.59 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, TAK or SMMT? Takeda Pharmaceutical has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.02, suggesting that its stock price is 202% less volatile than the S&P 500. Which has preferable earnings and valuation, TAK or SMMT? Takeda Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$30.09B1.63$712.33M$0.2269.91Summit Therapeutics$700K22,492.29-$221.32M-$0.34-62.35 SummaryTakeda Pharmaceutical beats Summit Therapeutics on 10 of the 17 factors compared between the two stocks. Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SMMT vs. The Competition Export to ExcelMetricSummit TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.80B$2.43B$5.48B$8.94BDividend YieldN/A1.79%5.38%4.12%P/E Ratio-62.358.7826.2119.74Price / Sales22,492.29636.32395.51109.12Price / CashN/A154.3736.4957.06Price / Book40.004.467.915.37Net Income-$221.32M$31.16M$3.15B$248.34M7 Day Performance-0.33%0.38%0.77%1.67%1 Month Performance19.57%8.14%3.46%4.56%1 Year Performance181.17%3.02%34.61%18.42% Summit Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SMMTSummit Therapeutics2.6319 of 5 stars$21.20-0.4%$34.67+63.5%+160.4%$15.80B$700K-62.35110Analyst UpgradeTAKTakeda Pharmaceutical1.229 of 5 stars$14.72-0.3%N/A+18.4%$46.84B$4.58T66.9149,281ARGXargenex4.3104 of 5 stars$540.76-0.3%$709.18+31.1%+24.9%$33.02B$2.25B33.361,599Trending NewsAnalyst ForecastONCBeOne Medicines3.4891 of 5 stars$257.51+4.2%$319.00+23.9%N/A$28.22B$3.81B-69.2211,000Gap UpBNTXBioNTech2.4665 of 5 stars$103.01-3.3%$137.86+33.8%+36.4%$24.76B$2.98B-30.306,772Gap DownTEVATeva Pharmaceutical Industries4.0507 of 5 stars$16.96+0.1%$24.44+44.1%+2.0%$19.45B$16.54B-14.7536,830ITCIIntra-Cellular Therapies0.9104 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.8921 of 5 stars$20.68-2.3%$39.17+89.4%-16.5%$13.26B$3.12B11.752,682High Trading VolumeRDYDr. Reddy's Laboratories3.0164 of 5 stars$15.31+0.5%$16.95+10.7%-1.0%$12.78B$3.81B23.2027,811Positive NewsASNDAscendis Pharma A/S3.5208 of 5 stars$175.78-0.6%$220.67+25.5%+28.4%$10.75B$393.54M-27.991,017VTRSViatris3.0314 of 5 stars$8.85-0.2%$10.40+17.5%-13.3%$10.39B$14.74B-2.7932,000 Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors argenex Competitors BeOne Medicines Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Viatris Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SMMT) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
